Children with Growth Hormone Deficiency Treated With Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years- enliGHten Trial Final Results
Treatment of pediatric GHD with lonapegsomatropin in the enliGHten trial provided robust growth outcomes and maintained a safety profile comparable to that of daily GH in a population with a broad range of pubertal statuses.
Authors
- Eric A. Huang
- Paul L. Hofman (ORCID: https://orcid.org/0000-0002-8995-8711)
- Elpis Vlachopapadopoulou (ORCID: https://orcid.org/0000-0001-5641-7081)
- Paul Thornton (ORCID: https://orcid.org/0000-0002-9706-5665)
- Sohair Abdelrahman
- Maria Korpal-Szczyrska
- Allison Komirenko (ORCID: https://orcid.org/0000-0001-8844-2804)
- Aimee D Shu (ORCID: https://orcid.org/0000-0003-1801-5289)
- Ulhas M. Nadgir
- Aristides K Maniatis (ORCID: https://orcid.org/0000-0002-6705-8579)
- Meng Mao (ORCID: https://orcid.org/0000-0001-8537-6637)
- Elena Aghajanova (ORCID: https://orcid.org/0000-0002-1324-6275)
- O. A. Malievskiy (ORCID: https://orcid.org/0000-0003-2599-0867)
- Katie A. Woods
- Carol Zhao
Institutions
- Sutter Health (US)
- University of Auckland (NZ)
- Cook Children's Medical Center (US)
- Ascendis Pharma (Denmark) (DK)
- Bashkir State Medical University (RU)
- University Clinical Centre (PL)
- Doernbecher Children's Hospital (US)
- Panagiotis & Aglaia Kyriakou Children's Hospital (GR)
- Yerevan State Medical University (AM)
Publication Details
- Journal
- Hormone Research in Paediatrics
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1159/000545064
- Citations
- 2
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 2.59